Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASTE Study of prophylactic skin care before enfortumab vedotin
jRCTs031220257Active, not recruiting
- Sponsor
- University of Tsukuba Hospital
- Start
- Apr 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of enfortumab vedotin and mucopolysaccharide polysulphate in transitional cell carcinoma (TCC), sponsored by University of Tsukuba Hospital. Primary endpoint: Incidence of Grade 2 or higher adverse skin events. Started Apr 2023; status: active, not recruiting.
02
Drugs
enfortumab vedotinmucopolysaccharide polysulphate
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCTs031220257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220257.